S
SymBio Pharmaceuticals
SymBio Pharmaceuticals aims to develop drugs for patients overlooked by the industry, ensuring vital treatments reach those in need
About SymBio Pharmaceuticals
SymBio Pharmaceuticals is a Japanese pharmaceutical company focused on the development and commercialization of drugs for oncology, hematology, and autoimmune diseases. The company acquires promising drug candidates from a global network of biopharmaceutical companies and academic institutions, focusing on treatments with a high unmet medical need, even in smaller markets. SymBio's business model centers on in-licensing drug candidates that have already shown proof-of-concept in humans, thereby reducing the risk and time associated with early-stage drug discovery. The company then manages the clinical development, regulatory approval, and commercialization of these drugs, primarily in Japan and other Asian markets. Its revenue is generated through the sale of its approved pharmaceutical products. SymBio's client base consists of healthcare providers, hospitals, and pharmacies that treat patients with rare and difficult-to-treat diseases.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 2005
- Headquarters
- Tokyo, Japan
- Listing
- IPO 2011
- Sector
- Biotech & Life Sciences
News
Open roles
SymBio Pharmaceuticals in the Tokyo ecosystem
The SymBio Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
DBJ Capital
Series A9 investors entered at this stage
Daiichi Sankyo
SBI Investment
Waseda University- VCVALUE CREATION
Japan Asia Investment- TNTNP
Mitsubishi UFJ Capital
Mizuho Capital- TCTokyo Small and Medium Business Investment & Consultation
Series B and later2 investors entered at this stage
Cephalon
Whiz Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about SymBio Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See SymBio Pharmaceuticals on the full Dealroom platform
Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

